We measure what truly matters – cellular avidity – helping you uncover the next blockbuster therapies in your pipeline, faster and with confidence.
We measure what truly matters – cellular avidity – helping you uncover the next blockbuster therapies in your pipeline, faster and with confidence.
Our service accelerates immune cell discovery and validation with cutting-edge, high-throughput avidity measurements, empowering you to uncover the next blockbuster drug hidden in your pipeline with reliable, physiologically relevant insights.
Start your journey with a tailored consultation, where you will meet one of our scientists. We are keen to learn about your project and will walk you through our avidity-based services and capabilities. Together, we will explore your goals and co-develop a clear project schedule aligned with your pre-clinical research and development needs.
Whether you are validating T-cell receptor candidates or exploring other modalities, our team is here to ensure your success starts with a smart, well-informed plan.
In this phase, we collaborate with you to design the experiment from the ground up. We’ll define the ideal immune and target cell types, establish any special requirements (e.g. patient-derived or engineered cells), and align on control parameters and downstream assays.
Our platform can be adapted to any adherent tumour cells and immune cell type — from TCR-T to CAR-iNKT — giving you complete flexibility to match your therapy development goals. Expect a robust plan optimised for throughput, relevance, and actionable insight.
Once your experiment is live, we execute your project using our proprietary microfluidic platform. We will identify, characterise, and isolate viable, high-avidity immune cells, delivering clean, publication-ready datasets. Each project concludes with a comprehensive report, and optional follow-up session with our scientists to review results.
Whether you are validating IND candidates or screening for lead TCRs, we provide the clarity and speed your pipeline deserves.
Download our brochure to explore Avigen’s capabilities and services supporting biotech, pharma, and research teams.
Download our brochure to explore Avigen’s capabilities and services supporting biotech, pharma, and research teams.
TCR T
CAR-iNKT
Cell engagers
CAR-T
NK
CAR-NK
